ChronoScale Corporation Common Stock (NASDAQ:CHRN) Stock Breaks Below 50-Day Moving Average - Here's Why

Key Points

• CHRN fell below its 50-day moving average, trading as low as $18.21 before closing at $18.59, compared with a 50-day average of $20.43.
• Analyst sentiment is mixed: coverage includes Buy, Hold, and Sell ratings, resulting in an overall “Hold” consensus and an average price target of $19.00. Northland Securities issued an Outperform rating with a $32 target, while Weiss Ratings downgraded its Sell rating.
• The company reported a quarterly loss of $0.12 per share on $18.4 million in revenue and continues to face weak profitability, including a negative net margin of 135.66% and negative return on equity of 197.81%.

ChronoScale Corporation Common Stock (NASDAQ:CHRN - Get Free Report) passed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $20.43 and traded as low as $18.21. ChronoScale Corporation Common Stock shares last traded at $18.59, with a volume of 108,216 shares changing hands.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on CHRN shares. Weiss Ratings lowered shares of ChronoScale Corporation Common Stock from a "sell (d)" rating to a "sell (d-)" rating in a research report on Friday, September 25th. Northland Securities assumed coverage on shares of ChronoScale Corporation Common Stock in a research report on Friday, September 18th. They issued an "outperform" rating and a $32.00 target price on the stock. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, ChronoScale Corporation Common Stock currently has an average rating of "Hold" and an average target price of $19.00.

ChronoScale Corporation Common Stock Trading Down 2.3%

The business has a 50 day simple moving average of $20.43 and a two-hundred day simple moving average of $17.98. The company has a current ratio of 0.51, a quick ratio of 0.51 and a debt-to-equity ratio of 0.06. The company has a market cap of $2.71 billion, a PE ratio of -3.46 and a beta of 0.98.

ChronoScale Corporation Common Stock (NASDAQ:CHRN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 19th. The company reported ($0.12) EPS for the quarter. The business had revenue of $18.40 million during the quarter. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 197.81%.

Institutional Investors Weigh In On ChronoScale Corporation Common Stock

An institutional investor recently raised its position in ChronoScale Corporation Common Stock stock. Roble Belko & Company Inc raised its holdings in shares of ChronoScale Corporation Common Stock (NASDAQ:CHRN - Free Report) by 104.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,338 shares of the company's stock after buying an additional 1,195 shares during the period. Roble Belko & Company Inc owned about 0.07% of ChronoScale Corporation Common Stock worth $25,000 at the end of the most recent reporting period. 6.42% of the stock is owned by hedge funds and other institutional investors.

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.